Global Oncology And Neurology Disorder Drugs Market Size By Type (Product Type I, Product Type II), By Application (Application I, Application II), By Region, And Segment Forecasts, 2023 to 2032

The Global Oncology and Neurology Disorder Drugs Market was valued at USD 145.7 billion in 2023 and is projected to reach USD 265.8 billion by 2031, growing at a CAGR of 7.9% during the forecast period from 2023 to 2031. The market is driven by the escalating prevalence of cancer and neurological disorders, continuous R&D activities in targeted therapy and immunotherapy, and increasing government and private sector healthcare investments. Additionally, the rising aging population, heightened awareness about early diagnosis, and growing access to advanced treatments across emerging economies further bolster market growth.

Drivers:

1. Rising Global Disease Burden:

The increasing incidence of cancer types such as breast, lung, and colorectal cancer, along with neurological disorders like Alzheimer’s disease, Parkinson’s disease, and epilepsy, is a key driver for the demand for effective drug therapies.

2. Advancements in Drug Development:

The emergence of next-generation therapeutics—including monoclonal antibodies, gene therapies, and personalized medicine—is transforming treatment paradigms, improving survival rates, and fueling market expansion.

3. Increased R&D and Investment:

Major pharmaceutical firms and biotech companies are investing heavily in pipeline drugs and breakthrough innovations, supported by favorable regulatory policies and accelerated approval pathways.

Restraints:

1. High Treatment Costs:

The cost of oncology and neurology drugs remains a significant barrier to access, especially in low- and middle-income countries. High R&D and commercialization expenses contribute to premium pricing.

2. Side Effects and Drug Resistance:

Adverse effects associated with chemotherapy and targeted therapies, along with increasing resistance to existing treatments, pose clinical challenges, potentially limiting long-term treatment adherence.

Opportunity:

1. Growth in Emerging Markets:

Rising healthcare infrastructure, increased insurance coverage, and governmental initiatives in Asia-Pacific, Latin America, and the Middle East present untapped potential for drug manufacturers.

2. Expansion of Precision Medicine:

The integration of genetic profiling, AI-based diagnostics, and biomarker development opens new avenues for customized treatments in oncology and neurology, offering targeted efficacy with minimal side effects.

Market by System Type Insights:

By system type, the Targeted Therapy segment dominated the oncology market in 2023 due to its ability to selectively attack cancer cells with minimal harm to healthy cells. In neurology, the Biologics segment led in revenue, particularly in treating multiple sclerosis and Alzheimer's disease. These segments are anticipated to continue their leadership owing to favorable clinical outcomes and ongoing innovation.

Market by End-use Insights:

Hospitals and Cancer Treatment Centers accounted for the largest market share in 2023, supported by rising inpatient admissions, availability of advanced drug regimens, and multidisciplinary care approaches. Specialty Clinics are projected to grow rapidly due to their focus on outpatient care, convenience, and increasing number of neurologists and oncologists operating outside traditional hospital settings.

Market by Regional Insights:

North America led the global market in 2023, attributed to robust healthcare infrastructure, high per capita expenditure, and extensive adoption of innovative therapies. Asia-Pacific is expected to witness the fastest growth during the forecast period, driven by expanding patient base, medical tourism, and increasing clinical trials in oncology and neurology.

Competitive Scenario:

Key players in the Global Oncology and Neurology Disorder Drugs Market include Pfizer Inc., Novartis AG, Roche Holding AG, Merck & Co., Inc., Bristol-Myers Squibb Company, Sanofi, Johnson & Johnson, Biogen Inc., Amgen Inc., and Eli Lilly and Company. These companies are actively engaging in strategic alliances, new product launches, and pipeline expansions.

In 2024, Novartis received FDA approval for a first-in-class brain tumor therapy targeting aggressive glioblastoma.

Biogen announced a landmark acquisition of a neurology-focused biotech in early 2025 to expand its Alzheimer’s portfolio.

Pfizer and Merck entered a co-development agreement in 2023 for a dual-action cancer immunotherapy drug.

Scope of Work – Global Oncology and Neurology Disorder Drugs Market

Key Market Developments:

June 2024: Roche launched a novel antibody-drug conjugate for metastatic breast cancer in multiple markets across Europe.

February 2025: Johnson & Johnson gained conditional EMA approval for a Parkinson’s disease therapy utilizing stem-cell technology.

September 2023: Amgen expanded its oncology R&D hub in Asia-Pacific, targeting region-specific tumor types for drug development.

FAQs:

1) What is the current market size of the Global Oncology and Neurology Disorder Drugs Market?

The market was valued at USD 145.7 billion in 2023.

2) What is the major growth driver of the Global Oncology and Neurology Disorder Drugs Market?

The primary driver is the increasing prevalence of cancer and neurological disorders coupled with innovations in targeted and personalized drug therapies.

3) Which is the largest region during the forecast period in the Global Oncology and Neurology Disorder Drugs Market?

North America held the largest market share in 2023, while Asia-Pacific is expected to grow the fastest.

4) Which segment accounted for the largest market share in the Global Oncology and Neurology Disorder Drugs Market?

The Targeted Therapy segment in oncology and the Biologics segment in neurology led the market in 2023.

5) Who are the key market players in the Global Oncology and Neurology Disorder Drugs Market?

Key players include Pfizer Inc., Novartis AG, Roche Holding AG, Merck & Co., Inc., Biogen Inc., Johnson & Johnson, and Amgen Inc.